Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06698497 · ClinicalTrials.gov registry record · NA

Boosting COVID-19 Vaccination Uptake Using Wastewater Surveillance

A NA study, sponsored by Syracuse University.

Completed
Registry status
NA
Development phase
40
Enrollment target

NCT06698497: Completed NA study, sponsored by Syracuse University.

NCT06698497 is a NA study that has completed, run by Syracuse University. The registered enrollment target is 40 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06698497, a NA study, has completed, sponsored by Syracuse University.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target

Study Summary

Vaccinations are among the most successful and critical public health interventions. Despite the enormous protection that vaccines provide to public health, both delays and refusals of vaccines (vaccine hesitancy) are on the rise. Given that low vaccination rates present both an individual and community risk, it is critical that measures are taken to increase vaccination uptake in both rural and urban counties in New York. Wastewater surveillance of SARS-CoV-2 has been shown to be a leading indicator of pending surges. This study will examine whether a communications campaign based upon SARS-CoV-2 wastewater surveillance data can increase COVID-19 vaccine uptake. Forty counties have been selected for the communication campaign (20 in the treatment group and 20 in the control group). A difference-in-differences method will be applied to assess the impact of the communications campaign on vaccine uptake, which observes the outcomes between a control and treatment group over pre- and post-intervention time periods. The communications campaign will be evaluated using the change in vaccination status of residents of the treatment and control counties. Outcomes will also be compared between demographic groups including race and ethnicity because of differences in vaccination rates that have been already observed. We hypothesize that information regarding COVID-19 provided by wastewater surveillance that is geographically based and more local to communities will increase COVID-19 vaccine uptake. This theory of local information having an impact on health behavior is a novel application of the health belief model to increase vaccine uptake.

Primary Outcome

The change in vaccination coverage among residents of the counties in the study will be measured as the percent of the population that received a vaccine dose.

Interventions

  • BEHAVIORAL Communication Campaign

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-09-13
Est. Completion 2025-07-10
Phase NA
Syracuse University

31 total trials

What the finished NCT06698497 record still lists

NCT06698497 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which Communication Campaign is the first listed.

NCT06698497 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06698497 about?

NCT06698497 is a clinical study titled "Boosting COVID-19 Vaccination Uptake Using Wastewater Surveillance". Vaccinations are among the most successful and critical public health interventions. Despite the enormous protection that vaccines provide to public health, both delays and refusals of vaccines (vaccine hesitancy) are on the rise. Given that low vaccination rates present both an individual and commu...

What is the current status of trial NCT06698497?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2024-09-13. Estimated completion is 2025-07-10.

What interventions are being tested in trial NCT06698497?

The interventions under investigation include: Communication Campaign (BEHAVIORAL).

Who is sponsoring clinical trial NCT06698497?

This trial is sponsored by Syracuse University, which has 31 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06698497's enrollment target sits among peer trials

40 1447th of 2000 higher than 465 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06698497, the US trial registry maintained by the National Library of Medicine. NCT06698497 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.